WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
What are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4% to 7% in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also been seen in children and adolescents. The clinical course of GAD is often chronic, with 40% of patients reporting illness lasting >5 years. GAD is associated with pronounced functional impairment, resulting in decreased vocational function and reduced quality of life. Patients with GAD tend to be high users of outpatient medical care, which contributes significantly to healtcare costs. Currently, benzodiazepines and buspirone are prescribed frequently to treat GAD. Although both show efficacy in acute treatment trials, few long-term studies have been perform Benzodiazepines are not recommended for long-term treatment of GAD, due to associated development of tolerance, psychomotor impairment, cognitive and memory changes, physical dependence, and a withdrawal reaction on discontinuation. The antidepressant venlafaxine extended-release (XR) has received approval for the treatment of GAD in the United States and many other countries. Venlafaxine XR has demonstrated efficacy over placebo in two randomized treatment trials of 6 months' duration as well as in other acute trials. Paroxetine is the first of the selective serotonin reuptake inhibitors (SSRIs) to receive US approval for the treatment of GAD. Paroxetine demonstrated superiority to placebo in short-term trials, and investigations into the use of other SSRIs are ongoing. This suggests that other SSRIs, and serotonin and noradrenaline reuptake inhibitors, are likely to be effective in the treatment of GAD. Of the psychological therapies, cognitive-behavioral therapy (CBT) shows the greatest benefit in treating GAD patients. Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 1×
“GAD is frequently associated or comorbid with other mental disorders, such as major depression, dysthymia, panic disorder, and agoraphobia.(2) The mean age of onset of GAD appears to be in the late teens or early twenties.”
BackgroundBorkovec, T. D., & Costello, E. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.4.611 · Cited by 756
Gould, R. A., Otto, M. W., Pollack, M. H., & Yap, L. (1997) · Behavior Therapy · doi:10.1016/s0005-7894(97)80048-2 · Cited by 352
Self-citationThe epidemiology of generalized anxiety disorder
Kessler, R. C., Keller, M. B., & Wittchen, H.-U. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70204-5 · Cited by 337 · cited 5×
“The recognition that GAD and panic, although co-occurring, are sufficiently distinct to be considered independent disorders led to their separation in DSM-III.5 Early clinical studies evaluating GAD, as described by DSM-III, found that the disorder usually occurred in the These recommendations are based on proceedings…”
BackgroundMethodInfluentialWittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00002 · Cited by 299
Self-citationAllgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Self-citation
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Self-citationThe diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Tassone, D. M., Boyce, E., Guyer, J., & Nuzum, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.013 · Cited by 275
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
Metadata
- Authors
- Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2003-08
- Volume
- 8
- Issue
- S1
- Pages
- 53-61
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2113384447
- Cited by
- 93
- References
- 6
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. https://app.cochat.ai/papers/10.1017/s1092852900006945
- The paper
- Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003). WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. CNS Spectrums. https://doi.org/10.1017/s1092852900006945
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.